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Since the first successful percutaneous transluminal coronary angioplasty (PTCA) procedure 
carried out in 1977 by Andreas Grüntzig (1), interventional cardiology has undergone great 
advances. As a result, we are now able to offer patients minimally invasive revascularization 
in increasingly complex coronary arterial disease (CAD) scenarios, with high success and 
safety rates. Indeed, the current clinical practice guides recognize percutaneous coronary 
intervention (PCI) as the first choice revascularization technique in chronic ischemic heart 
conditions involving one- or two-vessel coronary disease. The technique is even clearly 
recommended in preference to surgical revascularization in the absence of involvement of the 
proximal segment of the anterior descending artery (2). In more complex scenarios such as 
triple-vessel coronary disease or left main coronary disease adequate assessment of the 
anatomical complexity is advised, based on the so-called Syntax score, which has been shown 
to be an independent long-term predictor of death or major cardiac or cerebrovascular events 
after PCI in these settings (3, 4). Accordingly, even in this increased risk scenario, if the 
predicted anatomical complexity is low (Syntax score < 22), percutaneous revascularization is 
regarded as first-line treatment on a par with surgical revascularization (except in triple-vessel 
disease in diabetic patients) (2). 
Nevertheless, in order to reach the current level of excellence in percutaneous coronary 
treatment, it has been necessary to go a long way, with much technological development and 
research. Such development would not have been possible without in-depth knowledge of the 
physiopathology of coronary atherosclerosis. The coronary artery wall consists of three layers 
which, from luminal to abluminal, comprise the intimal, medial and adventitial layers (Fig. 
1a, 1b). These in turn are respectively separated by two membranes: the internal and the 
external elastic laminas:  
                                                                          
                   








                                                                    
 
 
  1b. Coronary vessel wall components: correlation in optical coherence tomography images. 
 
While the adventitial layer (or tunica adventitia) is mainly composed of fibroblasts, the medial 
layer (or tunica media) mainly contains smooth muscle cells that afford arterial wall 
contractility. The composition of the intimal layer (or tunica intima) is more complex, with a 
monocellular lining on the intimal surface called endothelium, that constitutes an organ in 
itself, thanks to the synthetic capacity of the cells that conform it. One of the main functions 
of the endothelium is the regulation of vascular tone (and therefore of blood flow) through the 
release of both vasoconstricting substances such as endothelin-1 or thromboxane AII, and 
vasodilating substances such as nitric oxide (NO) or prostacyclins (5). The intimal layer also 
contains slightly thickened zones that have been referred to as “eccentric adaptive thickening 
zones”, and which are characterized by the presence of smooth muscle cells in the absence of 
lipids or foam cells. These zones are preferentially located in regions of increased flow or 
turbulent flow, such as the bifurcations or proximal segment of the anterior descending artery, 
and are regarded as zones associated to an increased risk of atherosclerosis. In fact, it is 
common for the first changes in the arterial wall to be detected in these adaptive thickening 
zones, with the presence of isolated foam cells (6). These changes are observed particularly in 
childhood, and it is believed that they still be able to undergo regression. However, they can 
also progress to give rise to what is typically called a “fatty streak”, representing a more 
advanced degree of intimal alteration characterized by a greater accumulation of foam cells 
(distributed in rows) together with smooth muscle cells exhibiting a slight lipid content. Thus, 
in this phase the main lipid deposits are located at intracellular level, and the changes are 
considered to still be potentially reversible (6). The above described changes are classically 
referred to as type I and type II lesions, respectively (Fig.2). Although the mechanisms 
favoring their progression are not well known, type III (or “pre-atheroma”) lesions are 
considered to be present when small lipid deposits are identified at extracellular level, with 
very slight displacement of the proteoglycan matrix and smooth muscle cells (6). As the lipid 








(or “atheroma”) lesions. These are characterized by the presence of a well-organized 
extracellular lipid core that displaces the usual intimal smooth muscle cells and extracellular 
matrix (7). It is also common to observe the development of capillaries close to the lipid core, 
with the presence of macrophages, foam cells and lymphocytes. However, in these type IV 
lesions the separation between the core and the endothelium is essentially at the expense of 
the layers of proteoglycan matrix of the tunica intima, which are displaced by the lipid 
material (with no significant increase in the number of smooth muscle cells or collagen). Once 
the atherosclerotic lesion has developed a thickened layer of fibrotic material (composed 
mainly of collagen), progression towards a type V lesion is considered to have occurred (7). 
This collagen is fundamentally produced by the existing smooth muscle cells, and it mostly 
consists of type I collagen. The type V lesions in turn are subdivided into type Va, Vb and Vc 
lesions, depending on their characteristics and the presence or absence of a lipid core (see fig. 
2 below). Based on this classification proposed by Stary (6, 7), both the type IV and the type 
V lesions can undergo ulceration, hemorrhage and thrombosis - becoming what are referred to 
as type VI lesions or complicated plaques (7).  
 
Stary classification of atherosclerotic plaques 
   
Fig. 2 Permitted by Wolters Kluwer Health. 
                          Stary et al. Arterioscler Thromb Vasc Biol. Sep;15(9):1512-31.(7) 
 
However, in the light of the results obtained from post-mortem studies on coronary disease in 
the context of sudden death, Virmani et al. in the year 2000 published a modification of the 
previously described classification of atherosclerotic lesions (8). This post-mortem study 
showed that arterial thrombosis is not always linked to plaque rupture or inflammation, and 
that the presence of apparently stable plaques (such as type Va, Vb and Vc lesions)(7) does 
not rule out the presence of past thrombotic events that have gone undetected due to their non-
occlusive nature or because of spontaneous lysis or recanalization. Considering the changes 










Fig. 3 Permitted by Wolters Kluwer Health. 
Virmani et al. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1262–1275(8) 
 
Although different major risk factors have been identified in the process of atherosclerosis, 
such as arterial hypertension, diabetes mellitus or smoking, dyslipidemia is regarded as the 
main precursor element in the progression of the disease. In the presence of excessive 
circulating LDL-cholesterol, the particles of the latter cross the endothelial barrier in a 
concentration-mediated process called transcytosis. This process can be facilitated in 
situations of endothelial activation, mediated by the vascular changes secondary to arterial 
hypertension, flow alterations, etc. At intimal level, the LDL-cholesterol particles bind to the 
extracellular proteoglycan molecules through apolipoprotein B, exposing them to molecular 
oxidation processes. The first oxidized LDL-cholesterol molecules (minimally modified LDL 
particles or LDLmm) produce endothelial cell activation or damage, triggering a 
proinflammatory cascade involving the expression (by the activated endothelial cells) of 
molecular adhesion factors such as VCAM-1 or MCP-1 (9). As a consequence, a significant 
percentage of circulating monocytes bind to the endothelial cells, becoming internalized 
within the intimal layer and transforming into macrophages. This monocyte-to-macrophage 
conversion process is mediated by the LDLmm molecules and by mediators released by T 
lymphocytes (10). The macrophages capture part of the oxidized LDL-cholesterol molecules 
present at subintimal level, accumulating them in small “droplets” of cytoplasmic cholesterol. 
These droplets in turn increase and merge to give rise to the so-called “foam cells”. On 
establishing a correlation with the classical stratification proposed by Stary, at this point we 
would have the so-called type I and type II atherosclerotic lesions (6). As mentioned above, 
these two lesions are potentially reversible, since in these early phases, the foam cells are still 
able to externalize the excess cholesterol to the endothelial membrane, with capture by the 





transport” towards the liver, where it is cleared. However, in the presence of permanently 
elevated LDL-cholesterol levels, together with conditions such as diabetes mellitus (where 
hyperglycemia favors oxidative states) (11), an increasing intracellular accumulation of LDL-
cholesterol would take place within the foam cells, no longer compensated by this reverse 
transport phenomenon. Finally, this leads to apoptosis of the mentioned cells and therefore to 
the extracellular accumulation of cholesterol, giving rise to type III lesions of the 
classification of Stary. If this process continues, the extracellular accumulation of cholesterol 
expands and becomes organized, giving rise to so-called atheroma lesions (type IV and V 
lesions) (7).  
Likewise, it has been shown that the interaction of LDLmm with the endothelial cells 
favors expression by the latter of increased BMP2 and alkaline phosphatase levels - both of 
these factors playing a key role in vascular calcification (12). Specifically, BMP2 stimulates 
osteoblast migration and differentiation, and acts as an osteogenic differentiation factor for 
smooth muscle cells. These cells experience progressive calcification favored by the presence 
of high alkaline phosphatase levels, with a secondary decrease in the levels of pyrophosphate 
(the main inhibitor of vascular calcification) (12).  
However, the presence of elevated circulating LDL-cholesterol levels in dyslipidemic 
individuals not only favors the development of atheroma plaques but has also been seen to 
cause vascular tone dysregulation, while the oxidized LDL-cholesterol molecules can produce 
a decrease in the expression of the eNOS enzyme. This implies a decrease in the synthesis of 
nitric oxide and hence a greater tendency towards vasoconstriction and the proliferation of 
smooth muscle cells (since it normally avoids binding to the respective growth factors) (10).  
At this point, and knowing the physiopathology underlying the development of advanced 
atherosclerotic lesions, we are able to understand - in accordance with the descriptions of 
Virmani et al. (8) - that atherosclerotic plaques exhibit different phenotypes. We not only 
observe fibro-atheromatous plaques but also eminently fibrous or calcified plaques. Likewise, 
it is clear that atherosclerotic plaques can not only experience rupture but also erosion or 
complicated calcification (Fig.4). Manifest or frank rupture occurs in atheroma plaques with a 
very fine fibrous layer (thickness < 65 µm). When this layer ruptures, the lipid core becomes 
externalized and, on coming into contact with the bloodstream, it activates the coagulation 
cascade - giving rise to intraluminal thrombus or clot formation. In the case of erosion, the 
fibrous layer does not rupture; rather, these are atherosclerotic plaques mainly composed of an 
accumulation of smooth muscle cells with zones characterized by the absence of a covering 
endothelial layer, where the thrombotic process is triggered. Thrombotic phenomena in 
relation to calcium nodules are attributable to the “eruption” of calcium through the intimal 






Fig. 4 Permitted by Wolters Kluwer Health. 
Virmani et al. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1262–1275(8) 
 
Likewise, it must be taken into account that apparently stable plaques can cause the death of 
the patient (8), since lesions that are sufficiently severe (stenosis > 70-75% with respect to the 
basal coronary diameter) imply a significant decrease in coronary blood flow. This leads to 
myocardial ischemia that can manifest as exertional or resting angina, but also as the 
development of heart failure, ventricular dysfunction or proarrhythmogenic conditions of 
variable severity.  
 Percutaneous coronary intervention was developed in the late 1970s with the aim of 
avoiding these complications and of improving the quality of life of patients with ischemic 
heart disease. As mentioned previously, the first successful percutaneous transluminal 
coronary angioplasty (PTCA) procedure was carried out in 1977 by Grüntzig (1), in a 38-
year-old male with significant single-vessel disease of the anterior descending artery. The 
scientific community was initially reluctant to expand the technique in view of the uncertain 
outcomes, high costs and the initial need to have a back-up surgical team available. However, 
the technique (which became known as POBA or “plain old balloon angioplasty”) gradually 
became incorporated to the hemodynamics units and underwent optimization thanks to greater 
knowledge of the procedure and improvements in the materials used. As an example, as the 
operators gained experience, routine simultaneous right-side catheterization was abandoned - 
this maneuver initially having been used to measure pulmonary pressure and for right 
ventricle overstimulation during balloon insufflation. Likewise, improvements in imaging 
techniques made it possible to obviate the measurement of distal pressure before and after 
angioplasty, in favor of visual guiding based on fluoroscopic images. The technological 
development of the materials used was both rapid and crucial for generalization of the 
technique. In particular, mention must be made of the decrease in caliber of the catheters used 
(from 9 French [F] initially to 4-6 F at present), the development of preformed catheters with 
side holes, new guides and balloons with improved crossing profiles, etc. Furthermore, the 
need for a back-up or standby surgical team was rejected after confirming that its presence did 
not result in significantly improved patient safety, since in general the delays and 





Therefore, this technique, involving the percutaneous dilatation of stenotic coronary 
lesions through the insufflation of sterile balloons mounted on a positioning catheter (guided 
by fluoroscopy) quickly became a widespread practice. There were some clear limiting 
elements, however (13), namely a high risk of acute reocclusion (usually secondary to the 
presence of residual dissections after balloon-mediated dilatation) and high restenosis rates 
over follow-up.  
Such restenosis over follow-up after POBA is mainly a consequence of two processes: 
a) Late recoil phenomenon, due to the viscoelastic properties of the 
arterial wall (14), whereby following dilatation the external elastic membrane 
tends to gradually return to its initial diameter.  
b) Late negative remodeling of the arterial wall. Following the vascular 
damage inherent to balloon-mediated dilatation of the arterial wall, a vascular 
healing response is activated, with local coagulation phenomena, cell proliferation 
and matrix synthesis at this level (15). Although this process is usually controlled 
and self-limiting, the mechanisms whereby it may prove more intense or persistent 
over time (giving rise to greater restenosis rates) are not fully clear. Some of the 
suggested factors promoting this anomalous response are the existence of flow 
alterations, greater previous plaque burden, or more aggressive dilatation 
procedures, for example.  
The first revolution within coronary interventionism was the introduction of the so-called 
conventional or bare-metal stents (BMS). The first coronary stent was implanted in 1986 by 
Puel and Sigwart, though the use of these devices did not become generalized until 
introduction of the so-called Palmaz-Schatz stent - the first stent to receive approval from the 
United States Food and Drug Administration (FDA). The main difference between the two 
devices was the self-expanding nature of the former versus balloon-controlled expansion of 
the Palmaz-Schatz stent. Bare-metal stents consist of a metal mesh that is released within the 
stenotic coronary lesion to open the artery and act as a scaffolding system maintaining 
adequate architecture of the vascular wall. Classical studies such as the BENESTENT I (16) 
or STRESS trial (17) showed BMS to overcome the main limitations found up until that time 
with POBA. In the acute phase, BMS prevented abrupt arterial occlusion secondary to simple 
post-dilatation dissections, thanks to their scaffolding effect. In turn, over the short-middle 
term, these stents reduced the high restenosis rates seen after POBA attributable to both late 
recoil (thanks to the vascular wall scaffolding action of the metal structure of the BMS) and to 
negative remodeling (since maintenance of an adequate vascular wall architecture, with 
laminar coronary flow, facilitated adequate vascular healing after initial wall damage inherent 
to the intervention). As a result, the need for repeat interventions targeted to the treated vessel 
was significantly reduced. 
Nevertheless, the permanent presence of a foreign body on the coronary arterial wall 
triggered a local intimal hyperplastic reaction which, in a large percentage of cases, produced 
significant reductions in intrastent luminal area. This was evidenced by a study published in 
1996 by Hoffman et al., involving intracoronary intravascular ultrasound (IVUS) follow-up 
(for an average of 5.4 months post-implantation) of 115 lesions treated with one or two 
Palmaz-Schatz stents (18). The mentioned study confirmed that the intrastent luminal loss 
detected after the placement of these devices was attributable to neointimal proliferation 
clearly visible in the intracoronary imaging studies. Although there were no differences in 





was moreover numerically correlated to an increase in neointimal tissue volume (18). These 
findings are consistent with those of other studies published during the same period, such as 
that of Dussaillant, which moreover found the use of smaller diameter stents to constitute a 
risk factor for restenosis (19).  
Histopathological studies have identified this neointimal proliferation as the result of 
pathological vascular remodeling secondary to the chronic mechanical damage caused by the 
sustained presence of the stent over the vascular wall. This permanent damage induces a 
feedback chronic inflammatory response of the vascular wall. The hyperplastic tissue at 
intimal level mainly consists of an accumulation of smooth muscle cells and fibroblasts 
within a collagen matrix. The formation of this pathological new tissue starts with the initial 
damage to the endothelium during the revascularization process. The damaged or “activated” 
endothelial cells undergo changes that result in:  
a) Dysregulation of eNOS activity (20), which leads to a decrease in NO 
levels, associated to an increase in inflammatory activity with increased 
concentrations of interleukins such as IL-5 and IL-6, stimulating factors such as 
GM-CSF or attractants such as MCP-1.  
b) Activation of circulating platelets upon coming into contact with the 
damaged endothelial cells, resulting in the formation of a platelet-rich thrombus 
over which leukocytes activated by the dysfunctional endothelium are seen to 
deposit.  
c) Activation of the so-called matrix metalloproteinases (MMPs). These 
zinc-dependent enzymes regulate the fragmentation of extracellular matrix 
proteins such as collagen or elastin (21). Increased activation of these enzymes 
therefore implies greater collagen and elastin fragmentation, which in turn 
constitutes a stimulus for a) the migration of smooth muscle cells from the medial 
to the intimal layer of the vascular wall, and b) for their proliferation and 
differentiation into secretory ( instead of contractile) cells (21,22). This 
differentiation contributes to perpetuate the inflammatory cascade, since the cells 
begin to secrete mainly growth factors, extracellular matrix, etc. 
The so-called drug-eluting stents (DES), which release different drugs at local level, were 
developed in an attempt to avoid the mentioned intimal hyperplastic phenomena. These 
devices consist of a metal skeleton with a polymeric matrix containing an immunosuppressor 
and antiproliferation drug substance that undergoes controlled release over the arterial wall. 
These immunosuppressors avoid the abovementioned smooth muscle cell proliferation (23), 
thereby impeding excessive intimal proliferation (24). 
This strategy results in a significant decrease in the incidence of stent restenosis, though 
at the expense of an increased thrombotic risk due to the presence of a foreign body in 
permanent contact with the arterial endothelium - thus making it necessary to subject the 
patient to prolonged antithrombotic treatment.  
The introduction over 10 years ago of the first bioresorbable scaffolds (BRS) led to a 
change in concept in interventional cardiology, and we now speak of endovascular therapy 
instead of coronary revascularization. These devices offer the benefits of BMS and DES, with 
the advantage of absorption of the scaffolding. This in theory would allow recovery of 
vascular motility and compliance, with an increase in luminal area and the theoretical 





The technological development of these devices was not simple. At first, any metal 
material forming part of their structure was discarded because of its permanent nature. 
Instead, different synthetic polymers were tested, such as polycaprolactone, 
polyhydroxybutyrate, polyorthoester, etc. However, these materials were discarded once the 
preclinical (non clinical) studies evidenced a strong inflammatory response with high 
neointimal proliferation rates after their implantation (26). Nevertheless, one material, poly-L 
lactic acid (PLLA), exhibited greater blood compatibility with favorable mechanical 
properties (27), and was thus used for the design of these devices.  
Thus, in 2004, Vogt et al. presented the first results following the implantation of 
resorbable scaffolds in a porcine coronary model. In this study the authors compared the 
histomorphometric and histopathological responses following the placement of two types of 
resorbable scaffolds: a) PLLA stent coated with paclitaxel; and b) uncoated PDLLA stent, 
versus the placement of BMS. The group receiving the polymeric scaffold coated with 
paclitaxel showed a significant decrease in neointimal area, with lower coronary restenosis 
rates after three months versus the other groups (coronary stenosis 49% versus 71% in the 
uncoated PDLLA group and 68% in the BMS group), with disappearance of the arterial 
scaffold structure (28).  
These promising results led to development of the first bioresorbable devices for 
implantation in humans - the first case series being published by Tamai et al. in the year 2000 
(29). The mentioned study evaluated the efficacy and safety of the so-called Igaki-Tamai 
stent: a bioresorbable stent comprising a polymeric PLLA scaffold with a zig-zag helicoid 
structure with no drug coating. A total of 25 devices were successfully implanted in 19 
coronary lesions, followed by angiographic and intracoronary imaging controls (IVUS) 
immediately after stent placement and after 24 hours and three and 6 months. Mechanical 
behavior was assessed in terms of minimum luminal diameter and stent and luminal cross-
sectional area, together with the degree of coverage over follow-up. After 6 months, adequate 
vessel expansion was seen to persist, with a degree of intimal hyperplasia no greater than that 
previously reported for BMS, together with a good clinical course - with no cases of stent 
thrombosis, death or acute myocardial infarction (29). This study for the first time evidenced 
the viability and safety of the use of bioresorbable polymeric scaffolding in coronary 
interventionism in human patients. Nevertheless, these results received a setback in 2001 with 
the publication of the data after 12 months of follow-up of over 60 lesions treated with the 
Igaki-Tamai stent, in which a high restenosis rate of about 19% was reported (30). 
In the light of these studies, it was concluded that bioresorbable polymeric stents could be 
an effective alternative in coronary revascularization, but that further technological 
development was needed in order to afford not only optimum transient protection against 
acute recoil and negative remodeling but also against restenosis derived from intimal 
hyperplasia secondary to placement of the device. Therefore, optimization of the concept of 
vascular therapy entailed the conversion of these resorbable scaffolds into local drug-eluting 
devices (as was previously achieved with the metal DES). In this regard, the American 
company Abbot® developed the first resorbable drug-eluting polymeric scaffold for human 
use: the so-called Absorb 1.0. This device consisted of a resorbable PLLA scaffold covered 
with a finer layer of PDLLA from which an antiproliferative drug (everolimus) was eluted in 
a controlled manner. Both polymers (PLLA and PDLLA) are fully bioresorbable thanks to 
hydrolysis in which each of the long chains of polymer are broken up into small particles 





following phagocytosis by the circulating macrophages. The duration of this resorption 
process was initially estimated to take two years, based on studies in a porcine model. The 
everolimus eluting period was much shorter, since the greatest percentage of the drug was 
released in the first three hours after placement of the stent (reaching a mean peak 
concentration in the luminal arterial wall of 15 ng/mg), though this process was continuously 
maintained during the first month, with 80% of total drug release being recorded 28 days after 
placement (31). 
The first results following implantation of this device were published in 2008, 
corresponding to what was known as the Absorb A cohort (31). This study involved 30 
patients with a single native vessel lesion (presenting a diameter of about 3 mm) and treated 
with a 12 or 18 mm Absorb 1.0 stent, depending on the length of the lesion. During stent 
placement, plaque predilatation was considered essential, postdilatation was regarded as 
optional, and the overlapping of bioresorbable devices was considered to be contraindicated. 
Clinical and angiographic follow-up (including imaging explorations) was carried out after 6 
months and two years. Clinically, only one adverse event was recorded over follow-up at 24 
months in the form of non-Q wave acute myocardial infarction. From the angiographic 
perspective, the rates were clearly higher than those of the metal DES in terms of in-stent late 
loss of up to 0.44 mm at 6 months (31) and 0.48 mm at 24 months (32). Although the 
neointimal area did not differ significantly from that quantified in studies with metal 
everolimus devices, a significant decrease in stent area was observed as assessed by IVUS - 
this implying a significant global reduction of the intrastent luminal area. It therefore was 
concluded that the antiproliferative drug elution process from the PDLLA coating was as 
effective as from permanent coatings, though conformational and design modifications of the 
device would be needed in order to avoid stent recoil (31). The introduction of these 
modifications resulted in the second generation of polymeric bioresorbable scaffolds in the 
form of Absorb 1.1. This new device maintained a PLLA scaffold with PDLLA coating, but 
with two fundamental differences: a zig-zag design with connecting bridges between the 
PLLA filaments affording greater radial strength without losing conformability (33), and 
small chemical variations in the nature of the polymer, resulting in slower hydrolysis (25).  
The efficacy and safety of Absorb 1.1 were evaluated in what is commonly known as the 
Absorb Cohort B trial. A total of 101 patients were included and subjected to clinical and 
multimodal (invasive and noninvasive) imaging follow-up. The reported major adverse 
cardiovascular events (MACE) rate was 9% (34) (understood as the combination of death due 
to cardiac causes, any myocardial infarction and target lesion ischemia guided 
revascularization). There were two main findings from the angiographic perspective:  
a) A marked decrease was observed in late lumen loss (LLL) (34) with 
respect to the data reported for Absorb A, after both 6 and 24 months (0.19 versus 
0.44 mm and 0.27 versus 0.48 mm, respectively) (31,32). 
b) Intracoronary optical coherence tomography (OCT) confirmed greater 
persistence over time of the polymeric scaffolding, with slower and more 
controlled resorption. Accordingly, 24 months after implantation, the number of 
clearly discernible struts in the Absorb A cohort was 34% lower than at the time of 
placement (32), versus practically all the struts found to be unaltered in the OCT 
study after 24 months in the Absorb B cohort (34).  
These favorable findings were consolidated after the publication in 2015 of the randomized 





everolimus-eluting platforms: bioresorbable polymeric stent (Absorb 1.1) versus permanent 
metal stent (Xience). Absorb was shown not to be inferior in terms of target lesion failure 
(TLF), and there were no significant differences in terms of target lesion revascularization 
(TLR) or stent thrombosis (ST) after 12 months (1.5% versus 0.7%; p = 0.13) (35). 
 On the basis of these findings, it was concluded that the polymeric bioresorbable 
devices are an effective and safe alternative in the treatment of uncomplicated native vessel 
lesions - affording sufficient arterial support to maintain arterial permeability, with adequate 
control of intimal proliferation. In this respect, Absorb 1.1 was the first BRS to obtain CE® 
and FDA® certification. 
Simultaneously, in view of the suboptimal results with low radial strength of the first 
polymeric BRS, the possibility was raised of developing metal-based resorbable devices 
capable of affording the same mechanical properties as the traditional chromium-cobalt DES, 
though in a temporary manner. After obtaining favorable results in the preclinical phase (36), 
Biotronik® for the first time developed and implanted a metal BRS in humans: AMS-1. This 
device consisted of a bioresorbable magnesium skeleton without drug coating and exhibiting 
rapid resorption (in less than 4 months). However, the initial results fell short of the 
expectations, with high target lesion revascularization rates over follow-up: 24% at four 
months and 45% at one year after implantation (37). These findings were attributed to a high 
late lumen loss rate, derived from a lack of intimal proliferation control (as this stent lacked a 
drug coating) and from the existence of an excessively rapid resorption process (4 months) 
leading to premature radial strength loss and secondary negative remodeling (37). 
In order to correct the weak points of this design, important structural changes were 
made, resulting in the so-called DREAMS-1 device. This was also a metal device (with a 
magnesium structure), but with two key modifications: a) a more controlled and prolonged 
resorption process (about 9 months); and b) the inclusion of a paclitaxel antiproliferative drug 
coating. These modifications resulted in clear improvement of the outcomes of coronary 
revascularization in humans, with a very significant decrease in the TLF rate (fundamentally 
at the expense of TLR), from 45% with the AMS-1 (37) to only 7% TLR after 12 months with 
the DREAMS-1 (38). However, over 12 months of follow-up, a significant decrease in 
minimum luminal area was observed, with late luminal loss rates higher than those reported 
for the coetaneous polymeric BRS: 0.39 mm at 12 months for DREAM-1 (38) versus 0.27 
mm at 24 months for Absorb 1.1 (34). New design changes were introduced to overcome 
these limitations, giving rise to the DREAMS 2G. This bioresorbable metal device (now 
known as Magmaris®) is fundamentally distinguished from the first-generation DREAMS 
design in that it possesses a sirolimus antiproliferative component within a PLLA matrix, with 
a slightly greater strut thickness (about 150 µm). This structural change affords optimum 
transient radial strength while maintaining a resorption time shorter than that of the polymeric 
BRS, due to its magnesium component (39). It has been estimated that 95% of the implanted 
magnesium is degraded within 12 months after stent placement (Fig.5), in the context of a 
two-phase process: a first step characterized by magnesium conversion to oxidized 
magnesium, followed by conversion of the oxidized magnesium to magnesium phosphate and 







Fig. 5 OCT evaluation of magnesium BRS 12 months after its coronary implantation. 
Struts are no longer visible 
 
Thanks to these changes, exceptional outcomes were achieved over 24 months of follow-up, 
with a TLF rate of 5.9% and an ischemia guided TLR rate of only 3.4% (40) - these rates 
being lower than those of the coetaneous polymeric Absorb 1.1 device, which presented a 
TLR rate at 24 months of 6% (41).  
Based on the favorable results obtained with both devices, Absorb 1.1 and Magmaris, in 
the respective pivotal studies (as described above), these designs were considered to constitute 
a safe and effective alternative in coronary revascularization in humans. In this way (after 
receiving CE® mark), these stents became common material in many cathlabs. Nevertheless, 
we consider that there was no solid scientific evidence of their behavior in different clinical 
scenarios outside the controlled setting of a clinical trial (e.g., coronary revascularization in 
the context of acute coronary syndrome [ACS], treatment of chronic occlusions, lesions over 
20 mm in length, etc.). The studies included in the present Doctoral Thesis were therefore 
designed to analyze the behavior of these devices in the real life setting from the clinical, 


















An evaluation was made of the efficacy and safety of bioresorbable devices in coronary 
angioplasty involving a non-selected cohort of patients in the real life setting, in different 
clinical scenarios.  
Objectives have been divided in two groups:  
-From the clinical perspective: the development of angina, myocardial 
infarction, death, stent thrombosis. 
-From a morphological perspective: intracoronary imaging parameters, 



























6. METHODS AND RESULTS 
 
Although the first studies with BRS yielded favorable results in application to coronary 
interventionism, the generalization of their use and the experience gained with longer follow-
up periods have raised concerns about their suitability and possible associated risks. With the 
publication in 2016 of the three-year follow-up findings referred to Absorb II (42), a higher 
LLL rate was detected (0.37 mm versus 0.25 mm), together with higher infarction rates 
secondary to target vessel revascularization (TVR) and definitive or probable stent 
thrombosis, in the group of patients treated with Absorb versus metal DES. Similar results in 
terms of an increased stent thrombosis rate associated to Absorb have been obtained in studies 
involving large patient samples, such as Absorb III (43), or in meta-analyses such as that 
published by Mahmoud et al. (44), alerting to a globally increased risk of definitive or 
probable stent thrombosis (relative risk [RR] 3.22) and very late thrombosis with these 
devices (RR 4.78). However, it should be noted that the pivotal studies of both (Absorb B and 
BIOSOLVE II) reported no cases of stent thrombosis (34, 40). Because of this, different 
theories were proposed regarding the possible causes of thrombosis with these devices - the 
initial studies suggesting defects in the implantation technique. Thus, stent malapposition or 
under-expansion, together with a lack of atheroma plaque coverage or distal dissections, were 
identified as causes of subacute thrombosis (45). 
With the aim fundamentally of avoiding the first two problems, the advisability of always 
performing final postdilatation after BRS placement was suggested in order to optimize the 
results obtained. However, this recommendation came into conflict with the alert raised by the 
hemodynamics laboratories following publication of the first case of strut rupture after 
Absorb implantation (46) and of a new case of device rupture after high pressure (20 and 16 
atm) postdilatation described by Ormiston et al. (47). The OCT follow-up data on 51 patients 
of the Absorb B cohort evidenced isolated acute disruption phenomena following placement 
of the stent, though the incidence was very low (48). Indeed, only two cases were identified, 
and in both of them high-pressure postdilatation was described during implantation, 
expanding the device to diameters above the established rupture threshold (> 0.5 mm with 
respect to nominal) (48). The problem was therefore attributed more to over-expansion of the 
device than to postdilatation. Nevertheless, the initial concern generated in the scientific 
community hindered the possibility of postdilatation of these devices, due to an eventual risk 
of rupture, with uncertain consequences.  
At that point it became necessary to clarify the relationship between postdilatation and 
strut rupture for polymeric BRS. With this purpose, the first study of this research project (49) 
was designed in the form of a prospective observational trial including all the patients treated 
with Absorb 1.1 in our laboratory between June and December 2015. On a per protocol basis, 
predilatation of the lesion and postdilatation of the device was performed in all cases with 
non-compliant (NC) balloons in 1:1 ratio with the artery and with a minimum pressure of 10-





OCT. The primary objective of the study was to quantify the percentage of ruptured struts 
following postdilatation, while the secondary objective was to evaluate the percentage of 
malapposed struts. A total of 14 patients were included (with 14 treated lesions). The subjects 
underwent percutaneous coronary intervention (PCI) in both a stable context (50%) and 
during acute coronary syndrome (ACS) (21% non-ST-segment elevation [ACS-NSTE] and 
29% ST-segment elevation myocardial infarction [STEMI]), with great lesion complexity 
(mostly type C lesions of the American Heart Association [AHA] classification). Pre- and 
postdilatation was performed in all cases, with a mean postdilatation pressure of 17 atm and a 
maximum pressure of 20 atm, with no incidents during the procedure (49). The current 
consensus was used for analyzing the OCT images (48), defining strut disruption as the 
presence of two struts in the same angular sector of the lumen, whether one over the other 
separated by a space (“overhung struts”) or in contact (“stacked struts”) (Fig.6). 
 
 
           Fig. 6 The letter A shows an example of “stacked struts” disruption 
 
Disruption was also considered to be present when “free” struts were identified within the 
lumen, with no connection to the circumference generated by the device - a situation known 







                      Fig. 7a Example of “isolated struts” disruption in a polymeric BRS 
 
                 
              Fig. 7b Example of a disrupted magnesium-BRS with “isolated struts” ( arrow) 
 and “ overhung struts” ( star) 
 
Out of a total of 39,590 struts analyzed, disruption was identified in only 0.22% (89 struts) 
(49).  
An analysis was subsequently made of the presence of incomplete strut appositioning 
(ISA) (Fig.8a, 8b), defined as the presence of a separation between the abluminal surface of 
the device and the endoluminal surface of the vessel, greater than the thickness of the strut of 
the device (50). Out of a total of 39,590 struts analyzed, 564 presented malapposition - this 







        Fig. 8a Example of acute malapposition after implantation of a polymeric BRS 
 
                   
         Fig. 8b OCT image of acute malapposition after implantation of a magnesium BRS 
 
These results strengthen the findings published practically at the same time by Fabris et al. 
(51), who reported a low percentage of malappositioned struts (1.84%) after high-pressure 
(maximum 30 atm) postdilatation in Absorb 1.1, with no detection of fractured struts. 
However, it should be noted that only 41% of the devices included in the study of Fabris et al. 
were subjected to postdilatation - in contrast to the situation in our laboratory, where 
postdilatation was performed in 100% of the cases, thereby avoiding any selection bias. 
 Therefore, our results evidence the scant impact of high-pressure postdilatation of the 
Absorb 1.1 in terms of strut disruption, provided such postdilatation is produced at high 
pressure, but with non-compliant balloons and in 1:1 ratio with the artery, in order to avoid 





these polymeric BRS is similar to that of BMS, the percentage elongation to rupture is smaller 
(2-10% versus 40% for chromium-cobalt devices)(25,48). Safe postdilatation affords highly 
optimized outcomes after placement, with low final malapposition rates (percentage ISA 
1.42%) - this being essential in order to reduce the risk of thrombosis of the device.  
Likewise, it should be underscored that our results are referred to a real population, not 
previously selected as in the pivotal studies in terms of the indication of revascularization 
(including patients with ACS) and lesion complexity (with a majority of lesions 
corresponding to type C of the AHA classification). Of the lesions included in our study, 28% 
presented thrombus, 21% were defined as lesions at bifurcations, and another 21% 
corresponded to chronic total occlusions (CTOs) (49) - all these being scenarios where the 
possibility of malapposition and under-expansion of the device are greater.  
It is precisely in this scenario of CTO revascularization where these BRS devices were 
postulated to offer greater benefit by avoiding permanent “full metal jacket” situations. 
However, this was also regarded as the field where BRS could pose greater technical 
limitations due to their lesser radial strength (25) in resisting negative remodeling and recoil 
phenomena. In order to gain more in-depth knowledge of the behavior of BRS in this context, 
a second study was designed, involving clinical and OCT follow-up over 6 months of 9 
chronic lesions treated with Absorb 1.1 in our laboratory (52). Exhaustive plaque preparation 
was made in all cases, and the outcome was optimized with high pressure (mean 16 atm and 
maximum 20 atm) postdilatation in 89% of the cases, achieving a procedure success rate of 
100%. In the OCT follow-up study, a total of 44,723 struts were analyzed, of which only 134 
were identified as being fractured - this representing a disruption rate of 0.29%. In this case, 
no struts were found to be malappositioned (52). These findings, which are consistent with 
those previously described (49), warrant the safety of high-pressure postdilatation of these 
devices, making it possible to obtain optimized outcomes even in scenarios as complex as 
chronic occlusions. 
Another key factor in the etiopathogenesis of stent thrombosis is the absence of strut 
coating. In 2007, Finn et al. presented a post-mortem study in patients carrying first 
generation DES, divided into two groups: stent-related death (when occlusive or non-
occlusive thrombus with distal embolization was observed) and non-stent related death (when 
the implanted DES showed no evidence of thrombosis or restenosis). The comparative 
analysis showed the cases of stent thrombosis to be associated to lesser neointimal coating in 
terms of both neointimal thickness and the length of uncoated stent (53). Later studies 
involving in vivo analysis based on intracoronary imaging techniques reinforce this idea. An 
analysis seeking to identify the causes of stent thrombosis in 217 cases found that the earlier 
stent thrombosis, the greater the presence of uncoated struts. In this regard, among the 
identifiable causes of stent thrombosis, in situations of acute and subacute thrombosis the 
main underlying cause was the absence of strut coating (66% and 61%, respectively) - the 
prevalence decreasing in the case of late thrombosis to 33% and particularly in very late 
thrombosis, where the presence of neoatherosclerosis was seen to predominate (54).  
Based on the type of lesion, observational studies such as the RESTART registry have 
established a special association between: a) PCI targeted to the culprit artery in infarction 
and a greater incidence of acute thrombosis (probably related to inadequate antiplatelet 
therapy, acute malapposition, the presence of thrombus or residual dissections); and b) PCI 
targeted to chronic occlusions and greater late / very late stent thrombosis rates (55). A priori, 





thrombosis in CTO is related to the presence of neoatherosclerosis combined with persistent 
under-expansion. However, following publication of the results of the ALSTER-OCT-CTO 
registry, it was suggested that the absence of strut coating could be the key factor also in the 
development of stent thrombosis over CTO subjected to PCI (56). This registry included 20 
chronic lesions and 28 non-CTOs subjected to intracoronary imaging study after 6 months. 
Out of a total of 9219 struts analyzed in the CTO group and 10,724 struts in the non-CTO 
group, the uncoated strut rate was found to be 31% in the CTO group versus 10% in the non-
CTO group - this representing a significantly greater percentage of absence of strut coating in 
the former group (p <0.001). However, not only was the coating rate lower but the neointimal 
thickness of the coated zones was also smaller (after a similar duration of follow-up) in the 
case of the struts of treated chronic lesions versus the non-CTOs (92 µm versus 109 µm; p = 
0.03) (56).  
Nevertheless, the evidence of a possible late or inadequate coating process in 
revascularization over CTOs was scarce, and since no data were available on the coating 
process of polymeric BRS devices in this context, we designed the previously described 
follow-up study after the revascularization of chronic lesions with Absorb 1.1 (52). Although 
other parameters such as strut malapposition or disruption were also evaluated, the primary 
objective of this study was to know the percentage of coated polymeric struts at 6 months 
post-implantation, together with the mean thickness of that coating. For this purpose 
intracoronary imaging studies were made using OCT and, in accordance with the literature, 
coated struts were defined as those with a coating measuring ≥ 30 µm as established from the 
abluminal margin of the strut to its core (57). A total of 44,723 struts were analyzed over a 
total stented length of 636 mm, with the identification of only 2051 uncoated struts - this 
representing 4.59% of the total. These data are consistent with those published practically at 
the same time by Vaquerizo et al. in their OCT follow-up study at 12 months post-BRS 
implantation in 24 chronic occlusions, where 5% of the struts were seen to lack coating (58). 
In addition, our study for the first time quantified mean strut coating thickness in CTOs, with 
a value of 0.13 ± 0.05 mm. 
These values were consistent with those previously described in studies of the coating of 
metal DES positioned in chronic occlusions (with an uncoated strut rate of about 3% and a 
mean neointimal thickness of 0.126 mm) (59), and with those reported for DES outside the 
context of CTO, with mean coating values of about 0.12 mm (60). 
Therefore, on the basis of these findings, it was concluded that drug-eluting BRS are as 
effective as permanent metal devices in controlling arterial healing, and that this process 
evolves similarly in both PCI targeted to chronic occlusion and in non-CTO of native vessels.  
Accordingly, it was considered that the greater stent thrombosis rates detected after PCI 
with polymeric BRS was related to a suboptimal revascularization technique. The so-called 
PSP technique (P - optimal Predilatation, S - vessel and device Sizing, and P - Postdilatation) 
was developed in an attempt to minimize these effects. In this respect, an adequate 
implantation technique was considered to comprise three steps (61): 
1. - Adequate assessment of the vessel reference diameter.  
Diameters suitable for placement of a polymeric BRS were considered to be ≥ 2.25 
mm to ≤ 3.75 mm according to quantitative coronary analysis (QCA) or between 2.5-4 





2.- Optimum predilatation, performed with balloons of a nominal diameter 
in 1:1 ratio with the vessel diameter according to QCA or visual assessment.  
3. - Final postdilatation, performed with non-compliant balloons with a diameter 
in no case > 0.5 mm with respect to the scaffold, and at high pressure (≥ 18 atm).  
Retrospectively, an evaluation was made of the impact which this optimized implantation 
technique could have upon the middle- to long-term clinical outcomes after PCI with 
polymeric BRS. To this effect, a review was made of all the cases of PCI with Absorb 1.1 
included to date in four large trials: Absorb II, Absorb Japan, Absorb III and Absorb China, 
plus those included in the Absorb Extend registry. It should be noted that out of a total of 
3149 lesions, 60% were considered to be adequately pre-dilated, while only 12.7% were 
considered to be adequately post-dilated. The stent thrombosis and target lesion failure (TLF) 
rates were recorded at one and three years, and those lesions treated with an optimized 
implantation technique were seen to show a significant decrease in the presence of these 
events (61). Subsequent real-life studies such as the GHOST-EU registry confirmed this 
significant decrease in events after the application of optimized implantation techniques, with 
a reduction of close to 30% (62). 
In view of these results, the decision was made to extend the recommendation to use a 
PSP optimization technique for the placement not only of polymeric BRS but also metal BRS 
(63). Nevertheless, this recommendation is not based on solid evidence, since in the pivotal 
study of the magnesium BRS (BIOSOLVE II) (39), only dilatation of the lesion prior to 
placement was considered mandatory - leaving postdilatation of the device to the discretion of 
the operator (69% of the cases) (40). In an attempt to clarify the relevance of an optimized 
implantation technique in the case of PCI with metal BRS, we designed a new prospective 
follow-up registry including all those patients treated with magnesium BRS in our center 
between June 2016 and April 2017 (64). In accordance with the above descriptions, and on a 
per protocol basis, exhaustive predilatation of the lesion and post-implantation high-pressure 
postdilatation of the device was performed with non-compliant (NC) balloons of a diameter in 
1:1 ratio with the scaffold (or no more than 0.5 mm greater). For adequate characterization of 
the size of the vessel (and thus of the scaffold to be used), we not only used visual 
angiographic assessment as reference but also performed a baseline intravascular OCT 
imaging study. Likewise, correct selection of the patients and target lesions was considered to 
be crucial. Accordingly, we mainly selected: a) young patients, where the benefits of a 
transient scaffold with eventual functional recovery of the vessel would afford benefits over 
follow-up; and b) native vessel lesions with no major calcium component and excluding 
complex scenarios such as the presence of left main disease or intrastent restenosis (64). It 
should be mentioned that this modified OCT guided implantation technique is known as the 
“4P” procedure.  
A total of 42 patients were included (with 42 treated lesions), using magnesium BRS, 
with a procedure success rate of 100% (defined as successful placement of the BRS device 
with final residual stenosis < 20% in the absence of complications such as death, acute 
myocardial infarction or TLR during hospital stay) (64). This evidences the importance of 
adequate characterization and preparation of the lesion to be treated with metal BRS, allowing 
our registry to reach an implantation success rate of 100% versus a lower rate (93% of device 
success) in the BIOSOLVE II trial, where the absence of adequate predilatation was identified 





From the clinical perspective, the existing evidence in relation to the results obtained 
after PCI with magnesium BRS was favorable but limited, being almost entirely based on the 
results of the pivotal studies: BIOSOLVE II and III (39,40,63). For this reason, the decision 
was made to define a primary clinical follow-up endpoint as the primary objective of our 
registry, in order to assess the results of the magnesium device in a real-life patient cohort.  
In this regard, the primary objective was established as the TLF rate at 12 months post-
implantation, defined as the combination of cardiac death, myocardial infarction related to the 
target vessel, and ischemia guided TLR.  
In a total of 42 lesions treated in our center (42 patients), the TLF rate at 12 months was 
4.7%, in relation to two cases of TLR due to restenosis of the previously implanted devices 
(64). These findings coincide with those published almost at the same time in January 2019 
corresponding to the BIOSOLVE IV study (65), a prospective multicenter registry developed 
in parallel to our own, with the start of patient recruitment in September 2016. In that study, 
out of a total of 400 patients with 425 treated lesions, Verheye et al. reported a TLF rate of 
4.3%, at the expense of TLR in all cases (65). It is important to point out that these results in 
the real life setting show continuity with those previously obtained in the BIOSOLVE II trial 
(with a TLF rate of 3.4%) (63), even though our registry includes patients and lesions with a 
greater risk profile (e.g., 54.7% of PCI in the context of ACS, 28.6% of patients with diabetes 
mellitus, and a longer stented vessel length of 21.6 mm versus 12.6 mm in the BIOSOLVE II 
trial) (39). All these results are not only encouraging in themselves but are moreover also 
comparable to those previously described for PCI with permanent DES (66).  
On the other hand, given the concern within the scientific community regarding the 
description of slightly higher late thrombosis rates after the placement of polymeric scaffolds, 
the results obtained in our series are encouraging, with a stent thrombosis rate of 0% at 12 
months post-implantation of magnesium BRS (64). These results are consistent with those 
obtained by the real-life BIOSOLVE IV registry, where no late stent thromboses were 
recorded after 12 months, and with a single episode of acute stent thrombosis (10 days after 
placement) in relation to very early suspension of the antiplatelet medication (65). Thus, solid 
evidence is produced that warrants the safety of metal BRS outside a controlled setting such 
as a clinical trial, where a 0% stent thrombosis rate at 24 months had already been reported 
(40). 
However, on the basis of these results, it is clear that the clinical behavior of metal BRS 
is not fully comparable to that of the polymeric devices, despite their common bioresorbable 
nature. Although the introduction of an optimized implantation technique resulted in a 
decreased risk of events after PCI involving polymeric BRS (62), follow-up studies have 
shown that the event rates for these devices - while decreased and considered to be acceptable 
- remain higher (about 5.5-7.1% at 24 months) (67,68) than in the case of magnesium BRS 
(40). 
In an attempt to clarify the mechanism underlying this disparity of results, we analyzed 
the data obtained in our comparative study between polymeric and magnesium BRS, the 
primary objective of which was the assessment (using intracoronary OCT) of the strut 
malapposition and disruption rates, together with the diameters corresponding to the lumen, 
scaffold and vessel in the immediate post-implantation period (69). A total of 10 lesions 
treated with PLLA BRS and 10 lesions treated with magnesium BRS were included, using a 





clinical-demographic perspective or in terms of the type of lesion - most cases corresponding 
to type B-C lesions of the AHA classification, with a mean vessel diameter of about 3.50 mm 
in both groups. Likewise, no significant differences were recorded in terms of the 
implantation technique, with the exception of the application of slightly higher postdilatation 
pressures in the metal BRS group (18.01±2.15 versus 17.20±3.80 atm; p=0.05). The analysis 
of the studies involving post-implantation OCT showed the magnesium BRS group to reach 
greater vessel and scaffold diameters (4.12±0.51 versus 4.04±0.46 mm; p=0.04 and 3.11±0.38 
versus 3.07±0.36 mm; p=0.03, respectively) (69). Taking into account that these were two 
well balanced groups of lesions in which the implantation technique did not differ 
significantly, these results were considered to support the idea of greater radial strength and 
expansion capacity of the metal BRS (63). Furthermore, no structural damage was detected, 
since the percentage of ruptured struts barely reached 0.15% - this figure in turn being 
significantly lower than the likewise low percentage recorded in the polymeric BRS group 
(0.15% versus 0.27%; p=0.03). This reaffirms the previous hypotheses that suggested a 
greater percentage elongation to rupture for these devices, based on the mechanical properties 
of magnesium (70). Likewise, the detection of lesser post-implantation eccentricity indices in 
the metal BRS group supports the data obtained in “in vitro” studies, where lesser rigidity and 
greater conformability of these devices was suggested (71).  
Thus, on the basis of described results, we consider polymeric and metal BRS to exhibit 
different mechanical properties, which rejects the idea of the existence of a “class 
phenomenon” attributable to their common resorbable nature. This mechanical behavior could 



























I/ BRS implantation is safe, with high procedural success rates and no peri-procedural major 
adverse cardiac events. 
II/ An optimized implantation technique must be performed to achieve those excellent 
angiographic and clinical outcomes, including an adequate assessment of the vessel reference 
diameter, as well as an exhaustive lesion predilatation and postdilatation of the scaffold 
deployed. 
III/ A complete evaluation with intracoronary imaging techniques, in particular OCT images; 
is mandatory in order to warrant an optimal vessel and lesion characterization and to evaluate 
immediate stent results after deployment. 
IV/ BRS postdilatation is safe, with very low rates of acute scaffold disruption; and it allows 
the operator to significantly reduce incomplete struts apposition.  
V/ Optimal post-implantation results are achieved after BRS PCI even in such complex 
scenarios as bifurcation lesions, long lesions or CTOs, as long as an optimized implantation 
technique is performed.  
VI/ Differences in acute mechanical performance between polymeric and metallic BRS have 
been detected, demonstrating greater percentage of elongation-at-break for magnesium 
devices. 
VII/ Mid-term vascular healing response in terms of struts coverage, after PLLA BRS 
deployment is comparable to vascular response after DES implantation, even in CTOs PCI 
VIII/ Long-term clinical outcomes after magnesium BRS PCI are excellent, with low TLR 
rates and no cardiovascular death or myocardial infarction; and consistent with those reported 
in its pivotal trial. 
IX/ Neither acute nor subacute stent thrombosis were detected after magnesium BRS PCI in a 
twelve-months follow-up after an optimized implantation technique.  
X/ Outside the controlled setting of randomized trials, the clinical and angiographic results 
obtained after resorbable platform implantation are largely dependent upon the use of 
optimized placement techniques. Under this premise, it is considered that such devices may 












8.  SPANISH ABSTRACT 
 
ESTUDIO DE EFICACIA Y SEGURIDAD DEL USO DE PLATAFORMAS DE 
ANDAMIAJE (STENTS) BIORESORBIBLES EN EL TRATAMIENTO DE LAS 
LESIONES CORONARIAS TRATADAS MEDIANTE ANGIOPLASTIA EN 
DIFERENTES ESCENARIOS CLÍNICOS. 
 
8.1 INTRODUCCIÓN 
Desde que Andreas Grüntzig realizara en 1977 con éxito la primera angioplastia coronaria 
transluminal percutánea (ACTP) (1), la cardiología intervencionista ha experimentado un gran 
desarrollo. Esto nos permite hoy en día ofertar a nuestros pacientes una revascularización 
mínimamente invasiva, en escenarios de enfermedad arterial coronaria cada vez más 
complejos, con altas tasas de éxito y seguridad.  
La primera revolución dentro del intervencionismo coronario se produjo con la 
introducción de los llamados stent metálicos o convencionales (BMS). Se trataba de 
dispositivos conformados por una malla metálica que se liberaba sobre la lesión coronaria 
estenosante consiguiendo la apertura arterial. Estudios clásicos como BENESTENT I (16) o 
STRESS trial (17) demostraron cómo los  BMS  superaban los principales limitantes hasta el 
momento en la angioplastia simple: la reestenosis a corto-medio plazo por mecanismo de 
recoil así como el desarrollo de remodelado negativo. Además, el implante de BMS prevenía 
la oclusión arterial abrupta secundaria a disecciones post-dilatación simple con balón de 
angioplastia.  
No obstante, la presencia permanente de un cuerpo extraño sobre la pared arterial 
coronaria desencadena una reacción local de hiperplasia intimal que, en un porcentaje elevado 
de casos, produce reducciones significativas del area luminal intrastent. Para evitar esto, se 
desarrollaron los llamados stent farmacoactivos (DES). Estos se componen de un esqueleto 
metálico sobre el cual se deposita un fármaco con propiedades inmunosupresoras 
antiproliferativas, el cual se libera de forma controlada sobre la pared arterial evitando la 
proliferación intimal excesiva (24).  Gracias a esto, se reduce de forma significativa el 
porcentaje de reestenosis de stent, pero a expensas de un aumento del riesgo trombótico 
derivado de la presencia de un cuerpo extraño en contacto permanente con el endotelio 
arterial (lo cual obliga a mantener al paciente bajo pautas prolongadas de tratamiento 
antitrombótico).  
Unificando los beneficios de BMS y DES pero con una diferencia fundamental: el 
proceso de resorción de su armazón; nacen los denominados dispositivos bioresorbibles 
(BRS). Los cuales permitirían teóricamente una recuperación de la vasomotilidad y 
compliance del vaso, con incremento del área luminal y la teórica desaparición del riesgo 





En su diseño inicial se evitó el uso de materiales de naturaleza metálica como parte de su 
estructura debido a su carácter permanente. En su lugar, se testaron diferentes polímeros 
sintéticos como: polycaprolactone, polyhidroxibutirato, polyorthoester, ácido 
poliglicólico…los cuales fueron desechados tras detectarse en estudios preclínicos una fuerte 
respuesta inflamatoria con altas tasas de proliferación neointimal tras su implante (26). Sin 
embargo, se observó que uno de ellos: el ácido poli-L-láctico PLLA,  presentaba mejor 
compatibilidad sanguínea con propiedades mecánicas favorables (27), por lo que se adoptó su 
uso para el diseño de estos dispositivos.  
En esta línea Vogt y colaboradores presentaron los resultados tras el implante de 
andamiajes resorbibles en un modelo coronario porcino. En este estudio se compararon las 
respuestas histomorfométricas e histopatológicas tras el implante de dos tipos de andamiajes 
resorbibles: a) stent de PLLA con recubrimiento de paclitaxel y b) stent de PDLLA no 
recubierto; frente al implante de BMS. Se demostró que el grupo de BRS polimérico 
recubierto de paclitaxel presentaba una reducción significativa del área neointimal con tasas 
menores de reestenosis coronaria  a 3 meses, con la desaparición del andamiaje permanente de 
la arteria (28).  
De forma casi paralela se publica la primera serie de casos de BRS en humanos por 
Tamai y colaboradores (29). En este estudio se testó la eficacia y seguridad del denominado 
stent de Igaki-Tamai: un stent bioresorbible conformado por un armazón polimérico de PLLA 
con estructura helicoidal en zig-zag, sin recubrimiento farmacológico. Se valoró el 
comportamiento mecánico en términos de diámetro mínimo luminal y área seccional luminal 
y de stent, así como grado de recubrimiento en el seguimiento. A 6 meses persistía una 
adecuada expansión del vaso, con un grado de hiperplasia intimal no superior a la 
previamente reportada para BMS, y con adecuado curso clínico evolutivo: sin casos 
detectados de trombosis de stent, muerte o infarto agudo de miocardio (29). No obstante, los 
resultados de seguimiento prolongado tras el implante de este dispositivo en series mayores 
de casos no fueron favorables; reportando elevadas tasas de reestenosis: 19% a 12 meses (30). 
A la luz de estos estudios, se concluyó que los dispositivos BRS debían aportar no sólo 
protección transitoria óptima frente al recoil agudo y remodelado negativo, sino también, 
frente a la reestenosis derivada de la hiperplasia intimal secundaria a su implante. Por tanto, 
debían convertirse en dispositivos liberadores de droga a nivel local. Así se desarrolló el 
primer andamiaje resorbible polimérico liberador de fármaco para uso en humanos: el 
llamado Absorb 1.0 Este dispositivo se componía de un armazón resorbible de PLLA, 
recubierto de una capa más fina de PDLLA desde donde se libera el fármaco antiproliferativo 
everolimus, en un proceso controlado donde el mayor porcentaje de fármaco se desprende en 
las primeras 3 horas tras el implante, completando un 80% de liberación a los 28 días post-
implante (31). Por su parte, ambos polímeros (PLLA y PDLLA) son completamente 
bioresorbibles gracias a un proceso de hidrólisis donde acabarán por degradarse en dióxido de 
carbono y agua. Este proceso de resorción se estimó inicialmente en unos 2 años de acuerdo 
con estudios en modelo porcino. 
Los primeros resultados tras implante de este dispositivo se publicaron en la denominada 
cohorte Absorb A (31), donde se incluyeron 30 pacientes con lesión única tratados con un 
dispositivo Absorb 1.0 Clínicamente se detectó un único evento adverso en seguimiento a 24 
meses en forma de infarto agudo de miocardio no-Q y, desde el punto de vista angiográfico, 
se observaron tasas claramente superiores a las de los DES metálicos en términos  de “in–





neointimal no difería de forma significativa con la cuantificada en estudios con dispositivos 
de everolimus metálicos, sí se observaba una reducción significativa del área de stent valorada 
por IVUS. Por tanto, se concluyó que el proceso de liberación de fármaco antiproliferativo 
desde un recubrimiento de PDLLA era eficaz, pero que debían realizarse cambios en el diseño 
del dispositivo para evitar fenómeno de recoil del stent (31). Como resultado, nace la segunda 
generación de BRS poliméricos Absorb 1.1 Este nuevo dispositivo mantenía un armazón de 
PLLA con recubrimiento de PDLLA, pero con dos diferencias fundamentales: un diseño en 
zig-zag con puentes de conexión entre los filamentos de PLLA que le confería una mayor 
fuerza radial sin perder conformabilidad (33), junto con pequeñas variaciones químicas en la 
propia naturaleza del polímero, que conllevaba un proceso de hidrólisis más lento (25).  
La seguridad y eficacia de Absorb 1.1 se testó en lo que se conoce como estudio Absorb 
Cohorte B, donde se incluyeron un total de 101 pacientes. La tasa de eventos adversos 
cardiovasculares mayores a 2 años reportada fue de 9% (34) (entendida como combinado de 
muerte de causa cardiaca, cualquier infarto de miocardio y revascularización guiada por 
isquemia de la lesión diana). 
Desde el punto de vista angiográfico, dos fueron los hallazgos principales:  
a)  Se observó una reducción marcada de los niveles de late luminal loss (LLL) 
(34) respecto a los reportados en Absorb A, tanto a 6 como a 24 meses (0.19 Vs 0.44 mm 
y 0.27 Vs 0.48 mm respectivamente (31, 32). 
b)  Se confirmó una mayor persistencia en el tiempo del andamiaje polimérico 
con un fenómeno de resorción más lento y controlado. A 24 meses tras el implante,  el 
número de struts claramente discernibles en la cohorte Absorb A era un 34%  menor que 
al implante (32) frente a la práctica totalidad de struts inalterados en OCT a 24 meses en 
la cohorte Absorb B (34).  
Estos resultados se vieron consolidados tras la publicación del estudio Absorb III (35) donde 
se comparaban los resultados tras el implante de sendas plataformas liberadoras de 
everolimus: bioresorbible polimérica (Absorb 1.1) y permanente metálica (Xience). Se 
demostró que Absorb no era inferior en términos de fallo de lesión diana (TLF) y que no 
existían diferencias significativas en términos de revascularización de lesión diana (TLR) o 
trombosis de stent (TS) a 12 meses (1.5% Vs 0.7%,  p 0.13) (35). 
 Ante estos hallazgos, se consideró que los BRS poliméricos constituían una alternativa 
eficaz y segura en el tratamiento de lesiones no complejas en vaso nativo por lo que Absorb 
1.1 fue el primer BRS en alcanzar la marca CE ® y FDA®.   
De forma simultánea, ante los resultados subóptimos con baja fuerza radial de los 
primeros BRS poliméricos, se planteó la posibilidad de desarrollar BRS de naturaleza 
metálica que pudieran aportar las mismas propiedades mecánicas que los DES de cromo-
cobalto, pero de forma transitoria. Tras obtener resultados favorables en fase preclínica (36), 
se desarrolla e implanta el primer BRS metálico en humanos: AMS- 1; conformado por un 
esqueleto de magnesio biodegradable, sin recubrimiento farmacológico y con tiempo de 
resorción inferior a 4 meses. No obstante, los resultados tras implante fueron negativos con 
altas tasas de TLR: 24 % a 4 meses y 45% acumulada a 1 año (37). Estos hallazgos se 
pusieron en relación con una alta tasa de LLL derivada: de un aparte de la ausencia de control 





la presencia de un proceso de resorción demasiado rápido que conllevaba una pérdida 
prematura de fuerza radial y remodelado negativo secundario (37).   
Con el fin de superar las debilidades de su predecesor se presenta el denominado: 
DREAMS-1. Un dispositivo que mantiene su naturaleza de magnesio pero con dos cambios 
fundamentales: a) un proceso de resorción más controlado y prolongado en el tiempo: en 
torno a 9 meses; y b) con presencia de recubrimiento farmacológico antiproliferativo de 
paclitaxel. Modificaciones que conllevan una optimización clara de resultados con una 
reducción muy significativa de las tasas de TLF (a expensas fundamentalmente de TLR) que 
pasaron de un 45% para el AMS-1 (37) a 7% de TLR a 12 meses en DREAMS-1 (38). Sin 
embargo se detectó, en el seguimiento a 12 meses, una reducción significativa del área 
mínima luminal, con tasas de LLL superiores a las reportadas por su BRS polimérico 
coetáneo (0.39mm a 12 meses para DREAMS 1 (38) Vs 0.27 mm a 24 meses para Absorb 
1.1) (34). Para superar estas limitaciones, se realizaron nuevas modificaciones que culminan 
con la presentación del DREAMS 2G. Este BRS metálico (actualmente denominado 
Magmaris ®) se diferencia fundamentalmente con el DREAMS-1 en que presenta un 
recubrimiento antiproliferativo de sirolimus, embebido en una matriz de PLLA, con un ligero 
mayor grosor de struts (en torno a 150µ). Esto le permite mantener una fuerza radial 
transitoria óptima, con un tiempo de resorción menor que el de los BRS poliméricos debido a 
su naturaleza de magnesio (39). Gracias a esto, se consiguieron resultados excepcionales en 
seguimiento a 24 meses, con tasas de TLF de 5.9% y de TLR guiada por isquemia de 3.4 % 
(40) ( lo que representa tasas menores a las de su coetáneo polimérico Absorb 1.1, el cual 
presentaba una tasa de TLR a 24 meses superior del 6% (41).  
A la luz de los resultados favorables obtenidos por ambos dispositivos: Absorb 1.1 y 
Magmaris en sus estudios pivotales, se consideró que representaban una alternativa segura y 
eficaz en el tratamiento de revascularización coronaria en humanos. No obstante, 
consideramos que no existía evidencia científica sólida acerca de su comportamiento en 
diferentes escenarios clínicos fuera del ambiente controlado de un ensayo como por ejemplo, 
en revascularización en el contexto de un síndrome coronario agudo, tratamiento de 
oclusiones crónicas, lesiones de longitud > 20 mm…Por esto motivo se diseñan los estudios 
incluidos en la presente tesis doctoral, con el fin de analizar el comportamiento de estos 
dispositivos en vida real: tanto desde un punto de vista clínico, como angiográfico y con 
técnicas de imagen avanzada.   
 
8.2 OBJETIVOS 
Evaluación de la seguridad y eficacia del uso de dispositivos bioresorbibles en angioplastia 
coronaria en una cohorte no seleccionada de pacientes en vida real, en distintos escenarios 
clínicos.  
Los objetivos se han dividido en dos grupos:  
- Desde un punto de vista clínico: desarrollo de angina, infarto de miocardio, 
muerte, trombosis de stent. 
- Desde un punto de vista morfológico: parámetros de imagen intracoronaria: 






8.3 MÉTODOS Y RESULTADOS 
Si bien los primeros estudios con BRS presentaban resultados favorables para su empleo en 
intervencionismo coronario, con la generalización de su uso y ante periodos de seguimiento 
más prolongados, surgen las primeras alarmas acerca de su idoneidad y posibles riesgos 
asociados. Con la publicación de los resultados de seguimiento a 3 años de Absorb II (42) se 
detecta una mayor tasa de LLL (0.37mm Vs 0.25 mm), junto con mayores tasas de infarto 
secundario a revascularización de vaso diana (TVR) y trombosis definitiva o probable de stent 
en el grupo de pacientes tratados con Absorb Vs DES metálico. Resultados similares, en 
relación con mayores tasas de trombosis de stent para Absorb, se detectan en estudios de gran 
volumen de pacientes como Absorb III (43) o en metaanálisis como el publicado por 
Mahmoud y colab. (44), donde se alertaba de un mayor riesgo global de trombosis de stent 
definitiva o probable (RR 3.22) así como de trombosis muy tardía para estos dispositivos (RR 
4.78). Sin embargo, cabe destacar que en los estudios pivotales de ambos dispositivos 
(Absorb B y BIOSOLVE II) no se reportó ningún caso de trombosis de stent (34, 40). Es por 
esto, que comienzan a desarrollarse distintas teorías acerca de las posibles causas de 
trombosis en estos dispositivos, apuntándose inicialmente a defectos en la propia técnica de 
implante. Así, se relacionó la presencia de malaposición o infraexpansión de stent, junto con 
la ausencia de recubrimiento de placa o disecciones distales como causa de trombosis 
subaguda (45).   
Para evitar fundamentalmente los dos primeros, se planteó la conveniencia de optimizar 
siempre el resultado tras implante de BRS mediante postdilatación final. Sin embargo, esta 
recomendación chocaba con la alerta surgida tras la publicación del primer caso de disrupción 
de struts tras el implante de Absorb (46) y de un nuevo caso de disrupción de dispositivo tras 
postdilatación a alta presión (20 y 16 atmósferas) por Ormiston y colab. (47). Los resultados 
de seguimiento por OCT en 51 pacientes de la cohorte B de Absorb evidenciaron aislados 
fenómenos de disrupción aguda tras el implante; no obstante, con muy baja incidencia (48). 
Apenas dos casos fueron detectados, y en ambos, se describía la postdilatación a alta presión 
durante el implante, hasta llevar al dispositivo a diámetros por encima del establecido como 
rotura (> 0.5mm respecto al nominal) (48). Por tanto, se planteó que no era tanto un problema 
de postdilatación sino más bien de sobreexpansión del dispositivo. No obstante, la inquietud  
generada entre la comunidad científica supuso un freno a la posibilidad de postdilatación de 
estos dispositivos ante un eventual riesgo de rotura, cuyas consecuencias eran desconocidas.  
En ese momento, surge la necesidad de esclarecer la relación entre postdilatación y 
disrupción de struts para BRS poliméricos. Con este fin se diseña el primer estudio de este 
proyecto de investigación (49): un estudio observacional prospectivo donde se incluyeron 
todos los pacientes tratados con Absorb 1.1 en nuestro laboratorio entre junio y diciembre de  
2015. Por protocolo, en todos los casos se realizaba predilatación de la lesión  y postdilatación 
del dispositivo con balones no compliantes (NC), en una relación 1:1 con la arteria y con una 
presión mínima de 10-12 atmósferas (atm). El resultado final se corroboraba por estudio de 
imagen intracoronaria mediante tomografía de coherencia óptica (OCT). El objetivo de 
estudio principal era la cuantificación del porcentaje de struts rotos tras postdilatación, 
valorando también como objetivo secundario el porcentaje de struts malapuestos. Se 
incluyeron un total de 14 pacientes, (14 lesiones tratadas) sometidos a intervencionismo 
coronario percutáneo (ICP)  tanto en contexto estable (50%), como durante síndrome 
coronario agudo (SCA) (21% sin elevación persistente del ST [SCASEST] y 29% con 





lesiones tipo C de AHA). Se realizó pre y postdilatación en el 100% de los casos, con una 
presión de postdilatación media de 17 y máxima de 20 atm, sin incidencias durante el 
procedimiento (49). Para el análisis sobre las imágenes de OCT, se siguió el consenso vigente 
(48) donde se definía la disrupción de struts como la presencia de dos struts en el mismo 
sector angular del lumen: tanto si están uno sobre el otro separados por un espacio “overhung 
struts” como si aparecen en contacto “stacked strus”.  Se consideraba también la presencia de 
disrupción cuando se detectaba la presencia de struts “libres” en el lumen, sin conexión con la 
circunferencia que genera el propio dispositivo, lo cual se conoce como “isolated struts”. De 
un total de 39590 struts analizados, se identificó disrupción en únicamente el 0.22% del total 
(89 struts) (49).  
Tras esto, se analizó la presencia de malaposición (ISA) definida como la presencia de 
una separación entra la cara abluminal del dispositivo y la endoluminal del vaso superior al 
grosor de strut del dispositivo (50). Del total de 39590 struts analizados se identificaron 564 
como malapuestos, lo que supone un bajo porcentaje de ISA de 1.42% (49).  
Estos resultados aportan solidez a los publicados de forma prácticamente coetánea por 
Fabris y colab. (51), donde se reportaba un bajo porcentaje de struts malapuestos (1.84%) tras 
postdilatacion a alta presión (máxima 30 atm) en Absorb 1.1, sin detección de struts 
fracturados. No obstante, cabe destacar que  únicamente el 41% de dispositivos incluidos en 
el estudio de Fabris y colab. se sometió a postdilatacion; a diferencia del estudio realizado en 
nuestro laboratorio, donde se practicó postdilatación en el 100% casos evitando así cualquier 
sesgo de selección.   
Por tanto, nuestros resultados evidencian la escasa repercusión que presenta el aplicar 
postdilatación a alta presión sobre Absorb 1.1 en términos de disrupción de struts, siempre y 
cuando dicha postdilatación se realice a alta presión pero, con balones no compliantes y en 
una relación 1:1 con la arteria, de forma que se evite cualquier fenómeno de sobreexpansión 
del dispositivo. Esto se debe a que, si bien la fuerza radial de estos BRS poliméricos es 
similar a la de BMS, no así su porcentaje de elongación a rotura que es menor (2-10% vs 40% 
para dispositivos de cromo-cobalto) (25, 48). Una postdilatación segura nos permite obtener 
tras el implante resultados muy optimizados con bajas tasas de malaposición final (porcentaje 
de ISA 1.42%), primordial para reducir el riesgo de trombosis de dispositivo.  
Asimismo cabe destacar que nuestros resultados aplican a una población real, no 
previamente seleccionada, en términos de indicación de revascularización (incluyendo 
pacientes con SCA) y de complejidad de lesión (con una mayoría de lesiones clasificadas 
como tipo C AHA). De entre las lesiones incluidas en nuestro estudio, un 28% presentaba 
trombo, un 21% se definían como lesiones en bifurcaciones y otro 21% se correspondían con 
oclusiones crónicas totales (OCT) (49), todos ellos escenarios donde la posibilidad de 
malaposición e infraexpansión del dispositivo son mayores.  
Es precisamente en el escenario de revascularización de OCT donde se planteó un posible 
mayor beneficio de estos dispositivos BRS  al evitar situaciones de “full metal jacket” 
permanente. Sin embargo, también se consideró que suponía el campo donde los BRS podrían 
presentar una mayor limitación técnica derivada de su menor fuerza radial (25) a la hora de 
soportar fenómenos de remodelado negativo y recoil. Con el fin de profundizar en el 
conocimiento sobre el comportamiento de BRS en este contexto, se diseña un segundo estudio 
en el que se completa seguimiento clínico y mediante OCT a 6 meses de 9 lesiones crónicas 





de placa en el 100% de casos y se optimizó el resultado con postdilatación a alta presión 
(media 16 atm. y máxima de 20 atm.) en un 89% de casos, consiguiendo una tasa de éxito del 
procedimiento 100%. En el estudio de seguimiento  por OCT se analizaron 44723 struts, de 
los cuales únicamente 134 se identificaron como fracturados, lo que supone un porcentaje de 
disrupción del 0.29%. En este caso, no se detectó la presencia de struts malapuestos (52). 
Estos resultados, en línea con los previamente reportados (49), apoyan la seguridad de la 
postdilatación a alta presión  de estos dispositivos, permitiendo la obtención de resultados 
optimizados incluso en escenarios tan complejos como el de las oclusiones crónicas. 
Otro de los factores clave identificados en la etiopatogenia de la trombosis de stent es la 
ausencia de recubrimiento de struts. Finn y colab. presentaron en 2007 un estudio post-morten  
en pacientes portadores de DES de primera generación divididos en dos grupos: muerte 
relacionada con stent ( cuando se evidenciaba presencia de trombo oclusivo o no-oclusivo con 
embolización distal ) y no-relacionada con stent ( cuando el DES implantado no presentaba 
datos de trombosis ni reestenosis) (53). En el estudio comparativo se observó que los casos de 
trombosis de stent se relacionaban con menor grado de recubrimiento neointimal: tanto en 
términos de grosor neointimal como de longitud de stent no cubierta (53).  Estudios 
posteriores con análisis in vivo mediante técnicas de imagen intracoronaria refuerzan esta 
idea. En un análisis dirigido a identificar las causas de trombosis de stent en 217 casos se 
observó que, cuanto más precoz era la trombosis stent, mayor la presencia de struts no 
recubiertos. Así, de entre las causas identificables de trombosis de stent, se observó que en 
trombosis aguda y subaguda la principal causa subyacente era la ausencia de recubrimiento de 
struts (66% y 61% respectivamente), bajando su prevalencia en los casos de trombosis tardía  
a un 33% y sobre todo, en los casos muy tardíos, donde predominaba la presencia de 
neoateroesclerosis (54).  
Atendiendo al tipo de lesión, estudios observacionales como el registro RESTART 
observaron que existía una especial relación entre: a)  ICP a arteria responsable de infarto con 
mayor tasa de trombosis aguda (en probable relación con antiagregación inadecuada, 
malaposicion aguda, presencia de trombo o disecciones residuales) e b) ICP a oclusiones 
crónicas con mayores tasas de TS tardía/muy tardía (55).  A priori y, de acuerdo con estudios 
previos, cabría pensar que este exceso de trombosis tardía en OCT se relacionaría con la 
presencia de neoateroesclerosis combinada con infraexpansion persistente. Sin embargo, tras 
la publicación de los resultados del registro ALSTER-OCT-CTO se sugirió que la ausencia de 
recubrimiento de struts podría ser un factor clave también en el desarrollo de TS sobre OCT 
sometidas a ICP (56). En este registro se incluyeron 20 lesiones crónicas y 28 no-OCT sobre 
las que se había realizado valoración con imagen intracoronaria a 6 meses. En un total de 
9219 struts analizados en el grupo OCT y 10724 struts en el grupo no-OCT, se identificó 
como struts no recubiertos un 31% en grupo OCT Vs 10%  en el grupo no OCT, lo cual 
representa un porcentaje significativamente mayor ( p<0.001) de ausencia de recubrimiento 
de struts en el grupo de OCT. Pero no sólo existían tasas menores de recubrimiento, sino que 
el grosor neointimal de las zonas recubiertas era menor (en un tiempo evolutivo similar) sobre 
los struts de lesiones crónicas tratadas frente a lesiones no OCT (92 µ Vs 109 µm,  p 0.03 
(56).  
Sin embargo, la evidencia disponible acerca de un posible proceso de recubrimiento 
tardío o inadecuado en revascularización sobre OCT era escasa y, dado que no existían datos 
acerca del proceso de recubrimiento de dispositivos BRS poliméricos en este contexto, 





crónicas con Absorb 1.1 (52) Si bien se evaluaron también otros parámetros como disrupción 
o malaposición de struts, el objetivo primario de este estudio era conocer el porcentaje de 
struts poliméricos recubiertos a 6 meses post-implante junto con el grosor medio de dicho 
recubrimiento. Para ello se realizaron estudios de imagen intracoronaria mediante OCT y, de 
acuerdo a la literatura previa,  se definieron como struts recubiertos aquellos que presentaban 
un recubrimiento ≥ 30 µm medido desde el borde abluminal del strut hasta su core (57).  Se 
analizaron un total de 44723 struts a lo largo de los 636 mm de longitud total stentada y se 
identificaron únicamente 2051 struts como no recubiertos, lo que supone un 4.59% del total. 
Estos resultados se mantenían en  línea con los publicados de forma prácticamente simultánea  
por Vaquerizo y colab. en su estudio de seguimiento con OCT a 12 meses tras el implante de 
BRS en 24 oclusiones crónicas, donde reportaban  un 5% de struts no recubiertos (58). De 
forma añadida, nuestro estudio cuantificó por primera vez el grosor medio de recubrimiento 
de struts poliméricos en OCT, siendo de 0.13± 0.05 mm. 
Estos valores se correlacionaban favorablemente con los previamente descritos en 
estudios de recubrimiento de DES metálicos sobre OCT (donde la tasa de struts no cubiertos 
rondaba el 3%, con un grosor neointimal medio de 0.126 mm) (59) así como en los reportados 
para DES fuera del contexto de OCT, con valores medios  de recubrimiento en torno a 0.12 
mm (60). 
Por tanto, a la vista de estos resultados, se consideró que los BRS liberadores de fármaco 
eran tan eficaces como los metálicos permanentes a la hora de controlar los procesos de 
healing arterial y que, este proceso transcurría de forma similar tanto en ICP a oclusión 
crónica como en lesiones de vaso nativo no OCT.  
De acuerdo con esto, se consideró que  las mayores tasas de trombosis de stent detectadas 
tras ICP con BRS poliméricos debían estar en relación con una técnica de revascularización 
subóptima. Para tratar de minimizar estos efectos se desarrolló la denominada técnica PSP, 
acrónimo en inglés de: “P- optimal Predilatation, S- vessel and device Sizing  y P-
postdilatation”. Así, se consideraba que una adecuada técnica de implantación requería de tres 
pasos (61): 
1/ Adecuada valoración del diámetro referencia del vaso.  
Se consideraban diámetros aptos para implante de un BRS polimérico si ≥2.25 hasta 
≤3.75 mm por “quantitative coronary analysis” (QCA) o entre 2.5  a 4 mm por valoración 
visual.  
2/ Predilatación óptima: realizada con balones con un diámetro nominal en relación 
1.1 con el diámetro del vaso por QCA/ visual.  
3/ Postdilatación final: realizada con balones NC con diámetro nunca >0.5mm 
respecto al del scaffold, y a alta presión (≥ 18 atm).  
De forma retrospectiva, se valoró el efecto que esta técnica de implante optimizada podía 
tener en los resultados clínicos a medio-largo plazo tras ICP con BRS poliméricos. Para esto 
se revisaron todos los casos de ICP con Absorb 1.1 incluidos hasta la fecha en 4 grandes 
ensayos: Absorb II, Absorb Japan, Absorb III y Absorb China; más los incluidos en el registro 
Absorb Extend. Cabe destacar que, en un total de 3149 lesiones, se consideraron como 
adecuadamente predilatadas el 60% de lesiones incluidas y, sólo un 12,7% como 
adecuadamente postdilatadas. Se identificaron las tasas de TS y TLF a 1 y 3 años y se observó 





reducción de estos eventos de forma significativa (61). Estudios posteriores en vida real como 
el registro GHOST-EU confirmaron esta  reducción significativa de eventos tras la aplicación 
de técnicas de optimización al implante, llegando a cuantificarse como una reducción  
próxima al 30% (62). 
A la luz de estos resultados se decidió extender la recomendación del empleo de una 
técnica PSP de optimización al implante no sólo para BRS poliméricos, sino también para 
BRS de naturaleza metálica (63). No obstante, dicha recomendación no se basa en la 
existencia de evidencia sólida al respecto dado que, en el estudio pivotal del BRS de 
magnesio (BIOSOLVE II) (39) únicamente se consideraba obligatoria la dilatación de la 
lesión previa al implante,  dejando la postdilatación del dispositivo a discreción del operador 
(69%  de casos) (40). Para tratar de esclarecer la relevancia de una técnica de implante 
optimizada en el caso de ICP con BRS metálicos, diseñamos un nuevo registro prospectivo de 
seguimiento donde se incluyeron todos aquellos pacientes tratados con BRS de magnesio en 
nuestro centro entre junio de 2016 y abril de 2017 (64). De acuerdo con lo previamente 
descrito, se realizaba por protocolo predilatación exhaustiva de la lesión y, tras el implante, 
postdilatación a alta presión con balones NC de diámetro  en relación 1:1 con el scaffold (o 
como máximo 0.5mm superiores). Para la adecuada caracterización del tamaño del vaso (y 
por ende, del scaffold a emplear) se decidió no sólo tomar como referencia una valoración 
angiográfica visual, sino completar el análisis con estudio por imagen intravascular con OCT 
basal. Asimismo, se consideró de vital relevancia el hacer una correcta selección de los 
pacientes y lesiones a tratar. Así se incluyeron principalmente a) pacientes jóvenes, donde los 
beneficios de un andamiaje transitorio con eventual recuperación funcional del vaso aportaría 
beneficios en el seguimiento y b) con lesiones en vaso nativo, sin un componente cálcico 
importante y excluyendo escenarios complejos como la presencia de enfermedad de tronco 
coronario o restenosis intrastent (64). Esta técnica modificada de implante guiada por OCT se  
denominó técnica “4P”.  
Se incluyeron un total de 42 pacientes con 42 lesiones tratadas con BRS de magnesio con 
una tasa de éxito de procedimiento del 100% (definido como implante exitoso del dispositivo 
BRS con estenosis residual final < 20% en ausencia de complicaciones tales como muerte, 
infarto de miocardio o TLR durante la estancia hospitalaria) (64). Esto pone de relevancia la 
importancia de la adecuada caracterización y preparación de la lesión a tratar con BRS 
metálicos, permitiéndonos alcanzar  en nuestro registro una tasa de éxito al implante del 100% 
frente a una tasa más reducida (93 % de éxito del dispositivo) en el estudio BIOSOLVE II, 
donde se identificó la ausencia de una adecuada predilatación como causa principal de dicho 
fracaso (39).  
Desde el punto de vista clínico, la evidencia existente en resultados tras ICP con BRS de 
magnesio era favorable pero escasa, basada prácticamente en exclusiva, en los resultados de 
los estudios pivotales: BIOSOLVE II y III (39, 40, 63). Por este motivo, se decide definir un 
objetivo primario de seguimiento clínico como objetivo principal de nuestro registro, con el 
fin de valorar los resultados del dispositivo de magnesio en una cohorte de pacientes en vida 
real.  
Se establece como objetivo primario la tasa de TLF a 12 meses tras implante, definida 
como el combinado de muerte cardiaca, infarto de miocardio relacionado con vaso diana y 





En el total de 42 lesiones tratadas en nuestro centro (42 pacientes) se reportó una tasa de 
TLF a 12 meses del 4.7% en relación con dos casos de TLR por restenosis de los dispositivos 
previamente implantados (64). Estos resultados son consistentes con los reportados de forma 
casi simultánea en enero 2019 en el registro BIOSOLVE IV (65), un registro multicéntrico 
prospectivo desarrollado de forma paralela al nuestro, con inicio de reclutamiento en 
septiembre de 2016. Donde, en un total de 400 pacientes con 425 lesiones tratadas, Verheye y 
colab. reportaron una tasa de TLF del 4.3% a expensas de TLR en todos los casos (65).  Es 
importante destacar que estos resultados en vida real muestran una línea de continuidad con 
los previamente descritos en el estudio BIOSOLVE II (con tasas de TLF del 3.4%) (63), 
incluso  cuando en nuestro registro se incluyen pacientes y lesiones con un mayor perfil de 
riesgo: ej. 54,7% de ICP en contexto de SCA,  28.6% de pacientes con Diabetes Mellitus y 
mayor longitud de vaso stentado (21,6 mm frente 12.6mm en BIOSOLVE II (39). Resultados 
todos ellos que no sólo son favorables en sí mismos, sino que además son comparables con 
los previamente descritos con ICP con dispositivos liberadores de fármaco permanentes (66).  
Por otro lado, dada la preocupación entre la comunidad científica a tenor de la 
descripción de tasas ligeramente superiores de trombosis tardía tras el implante de scaffold 
poliméricos, resultan alentadores los resultados obtenidos en nuestra serie con tasas de 
trombosis de stent del 0% a 12 meses tras el implante de dispositivos BRS de magnesio (64).  
Resultados consistentes con los publicados en el registro en vida real BIOSOLVE IV donde 
no se detectaron casos de trombosis tardía de stent a 12 meses, con un único episodio de 
trombosis de stent aguda ( a 10 días post implante) en relación con retirada muy precoz de 
tratamiento antiagregante (65). Por tanto, se genera evidencia sólida que refuerza la seguridad 
de los dispositivos BRS metálicos fuera de un ambiente controlado como es el del ensayo 
clínico, donde ya previamente habían demostrado una tasa 0% de trombosis de stent a 24 
meses (40). 
Sin embargo a la vista de estos resultados, queda patente que el comportamiento clínico 
de los BRS metálicos no se compara de forma total con el de los dispositivos poliméricos, 
pese a su naturaleza común bioresorbible. Aunque  la introducción de una técnica de implante 
optimizada permitía reducir el riesgo de eventos tras ICP con BRS poliméricos (62), en 
estudios de seguimiento se ha observado que las tasas de eventos para estos dispositivos, si 
bien se reducen y se consideran aceptables, se mantienen superiores (en torno al 5.5-7.1% a 
24 meses) (67, 68)  frente a sus homólogas reportadas para BRS de magnesio (40).  
Para tratar de dilucidar el mecanismo que lleva a esta disparidad de resultados, 
analizamos los resultados obtenidos en nuestro estudio comparativo entre BRS polimérico y 
de magnesio, cuyo objetivo primario consistía en la valoración (mediante imagen 
intracoronaria OCT) de los porcentajes de disrupción y malaposición de struts junto con los 
diámetros luminal, del scaffold y del vaso en el post-implante inmediato (69). Se incluyeron 
10 lesiones tratadas con BRS de PLLA y 10 con BRS de magnesio, todas ellas bajo una 
técnica de implante optimizada 4P.  No se identificaron diferencias significativas desde punto 
de vista clínico-demográfico ni en cuanto al tipo de lesión, siendo en su mayoría lesiones de 
tipo B-C AHA, con un diámetro medio del vaso en torno a 3.50 mm en ambos grupos. 
Tampoco se detectaron diferencias significativas en cuanto a la técnica de implante, a 
excepción de la aplicación de presiones de postdilatación ligeramente superiores en el grupo 
de BRS metálico (18.01±2.15 vs 17.20±3.80 atm, p=0.05). El análisis de los estudios con 
OCT post-implante demostró que, en el grupo de tratamiento con BRS de magnesio, se 





3.11±0.38 vs 3.07±0.36 mm, p=0.03, respectivamente) (69) Teniendo en cuenta que se trataba 
de dos grupos de lesiones bien balanceadas, donde  la técnica de implante no difería de forma 
significativa, se consideró que dichos resultados apoyaban la idea de una mayor fuerza radial 
y capacidad de expansión del BRS metálico (63). Todo ello, sin detectarse daños 
estructurales, dado que el porcentaje de struts identificados como rotos apenas alcanzaba  un 
0.15%;  el cual además, resultó significativamente inferior a la también baja tasa identificada 
en el grupo de BRS polimérico (0.15% vs 0.27%, p=0.03). Por tanto, se reafirman las 
hipótesis previas que sugerían un mayor porcentaje de elongación a rotura para estos 
dispositivos basándose en las propiedades mecánicas del magnesio (70). Asimismo, la 
detección de menores índices de excentricidad post-implante en el grupo de BRS metálico, 
apoya los datos presentados en estudios in vitro donde se sugería una menor rigidez y mayor 
conformabilidad de estos dispositivos (71). De acuerdo con los resultados descritos, 
consideramos que dispositivos BRS poliméricos y metálicos  presentan diferentes propiedades 
mecánicas, lo cual rechaza la idea de la existencia de un “fenómeno de clase” derivado de su 
naturaleza resorbible común. Comportamiento mecánico éste que podría subyacer en el 
distinto comportamiento evolutivo de estos dispositivos tras su implante.   
 
8.4 CONCLUSIONES 
I/ El implante de BRS es seguro, con altas tasas de éxito de procedimiento y sin eventos 
cardíacos mayores adversos periprocedimiento. 
II/ Con el fin de alcanzar la excelencia desde el punto de vista clínico y angiográfico, el 
implante se debe realizar bajo una técnica optimizada que incluya una adecuada valoración 
del diámetro de referencia del vaso, junto con una predilatación exhaustiva de la lesión a 
tratar y postdilatación del stent implantado. 
III/ Se considera obligada la realización de un estudio completo mediante técnicas de imagen 
intracoronaria, en particular estudio mediante OCT; con el fin de garantizar la adecuada 
caracterización del vaso y lesión diana así como la valoración de resultados en el post-
implante inmediato. 
IV/ La postdilatación de BRS se considera segura (con muy bajas tasas de disrupción aguda 
de strut); al tiempo que permite al operador reducir de forma significativa la tasa de aposición 
incompleta de strus. 
V/ Incluso en escenarios complejos para ICP con dispositivos BRS como son lesiones largas, 
en bifurcaciones u OCTs; se han conseguido resultados óptimos post-procedimiento gracias a 
la aplicación de una técnica optimizada de implante. 
VI/ Existen diferencias en el comportamiento mecánico agudo de BRS poliméricos y 
metálicos, con mayor porcentaje de elongación a rotura para los dipositivos de magnesio.  
VII/ La respuesta vascular a medio plazo tras implante de BRS de PLLA en términos de 
recubrimiento de struts es comparable a la respuesta tras implante de DES, tanto en un 
contexto CTO como no-CTO. 
VIII/ Los resultados a largo plazo tras ICP con BRS de magnesio han sido excelentes, con 





tiempo que consistentes con los previamente reportados en el estudio pivotal de este 
dispositivo. 
IX/ No se ha detectado ningún caso de trombosis de stent aguda o subaguda tras ICP con BRS 
de magnesio en un seguimiento a doce meses tras implante mediante técnica optimizada.  
X/ Fuera del ámbito controlado de los ensayos randomizados, los resultados tanto clínicos 
como angiográficos tras el implante de plataformas bioresorbibles dependen, en gran medida, 
de la aplicación de técnicas de implante optimizadas. Bajo esta premisa, se considera que 
estos dispositivos pueden suponer una alternativa eficaz en el tratamiento de revascularización 
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Polymeric and metallic bioresorbable vascular scaffolds 
were considered to constitute a safe and effective alternative 
in coronary revascularization in humans after clinical and 
angiographical favorable outcomes obtained in their 
respective pivotal trials. Nevertheless, we consider that there 
was no solid scientific evidence of their behavior in different 
clinical scenarios outside the controlled setting of a clinical 
trial. The prospective studies included in the present Doctoral 
Thesis were therefore designed to  evaluate the efficacy and 
safety of bioresorbable devices analyzing their behavior from 
the clinical, angiographic and advanced imaging 
perspectives. 
